Find Acoramidis Hydrochloride manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

Synopsis

ACTIVE PHARMA INGREDIENTS

0

API Suppliers

API Suppliers

0

USDMF

US DMFs Filed

0

CEP/COS

CEP/COS Certifications

0

JDMF

JDMFs Filed

0

EU WC

EU WC

0

KDMF

KDMF

0

VMF

NDC API

0

Listed Suppliers

Other Suppliers

API REF. PRICE (USD/KG)

$
$ 0

MARKET PLACE

0

API

0

FDF

0INTERMEDIATES

FINISHED DOSAGE FORMULATIONS

0

FDF Dossiers

FDF Dossiers

0

FDA Orange Book

FDA (Orange Book)

0

Europe

Europe

0

Canada

Canada

0

Australia

Australia

0

South Africa

South Africa

0

Listed Dossiers

Listed Dossiers

FDF Dossiers

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

0

Others

PATENTS & EXCLUSIVITIES

0

US Patents

0

US Exclusivities

0

Health Canada Patents

DIGITAL CONTENT

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

GLOBAL SALES INFORMATION

US Medicaid

NA

Annual Reports

NA

Finished Drug Prices

NA

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: Ag10 hydrochloride, Ag-10 hydrochloride, Alxn2060 hydrochloride, Acoramidis (hydrochloride), Alxn-2060 hydrochloride, Vy9c88c2nv
Molecular Formula
C15H18ClFN2O3
Molecular Weight
328.76  g/mol
InChI Key
MGFZEARHINUOMX-UHFFFAOYSA-N
FDA UNII
VY9C88C2NV

Acoramidis Hydrochloride
1 2D Structure

Acoramidis Hydrochloride

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
3-[3-(3,5-dimethyl-1H-pyrazol-4-yl)propoxy]-4-fluorobenzoic acid;hydrochloride
2.1.2 InChI
InChI=1S/C15H17FN2O3.ClH/c1-9-12(10(2)18-17-9)4-3-7-21-14-8-11(15(19)20)5-6-13(14)16;/h5-6,8H,3-4,7H2,1-2H3,(H,17,18)(H,19,20);1H
2.1.3 InChI Key
MGFZEARHINUOMX-UHFFFAOYSA-N
2.1.4 Canonical SMILES
CC1=C(C(=NN1)C)CCCOC2=C(C=CC(=C2)C(=O)O)F.Cl
2.2 Other Identifiers
2.2.1 UNII
VY9C88C2NV
2.3 Synonyms
2.3.1 Depositor-Supplied Synonyms

1. Ag10 Hydrochloride

2. Ag-10 Hydrochloride

3. Alxn2060 Hydrochloride

4. Acoramidis (hydrochloride)

5. Alxn-2060 Hydrochloride

6. Vy9c88c2nv

7. Acoramidis Hydrochloride [usan]

8. 2242751-53-5

9. Benzoic Acid, 3-(3-(3,5-dimethyl-1h-pyrazol-4-yl)propoxy)-4-fluoro-, Hydrochloride (1:1)

10. Unii-vy9c88c2nv

11. Chembl4650226

12. Schembl20475239

13. Acoramidis Hydrochloride [jan]

14. Hy-109165a

15. Cs-0143619

16. 3-(3-(3-5-dimethyl-1h-pyrazol-4-yl)propoxy)-4-fluorobenzoic Acid Hydrochloride

2.4 Create Date
2018-12-15
3 Chemical and Physical Properties
Molecular Weight 328.76 g/mol
Molecular Formula C15H18ClFN2O3
Hydrogen Bond Donor Count3
Hydrogen Bond Acceptor Count5
Rotatable Bond Count6
Exact Mass328.0989983 g/mol
Monoisotopic Mass328.0989983 g/mol
Topological Polar Surface Area75.2 Ų
Heavy Atom Count22
Formal Charge0
Complexity356
Isotope Atom Count0
Defined Atom Stereocenter Count0
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count2

NDC API

read-more
read-more

01

Pharma, Lab & Chemical Expo
Not Confirmed
arrow
arrow
Pharma, Lab & Chemical Expo
Not Confirmed

ACORAMIDIS HYDROCHLORIDE

NDC Package Code : 59116-5910

Start Marketing Date : 2021-12-30

End Marketing Date : 2024-12-31

Dosage Form (Strength) : POWDER (1kg/kg)

Marketing Category : BULK INGREDIENT

blank

02

Pharma, Lab & Chemical Expo
Not Confirmed
arrow
arrow
Pharma, Lab & Chemical Expo
Not Confirmed

ACORAMIDIS HYDROCHLORIDE

NDC Package Code : 59116-5911

Start Marketing Date : 2021-12-30

End Marketing Date : 2024-12-31

Dosage Form (Strength) : POWDER (1kg/kg)

Marketing Category : BULK INGREDIENT

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Drugs in Development

read-more
read-more

Details:

Attruby (acoramidis) is a next-generation, orally-administered, highly potent, small molecule stabiliser of transthyretin. It is approved for the treatment of Transthyretin Amyloid Cardiomyopathy.


Lead Product(s): Acoramidis Hydrochloride

Therapeutic Area: Genetic Disease Brand Name: Attruby

Study Phase: ApprovedProduct Type: Small molecule

Sponsor: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable November 22, 2024

blank

01

Pharma, Lab & Chemical Expo
Not Confirmed
Pharma, Lab & Chemical Expo
Not Confirmed

Details : Attruby (acoramidis) is a next-generation, orally-administered, highly potent, small molecule stabiliser of transthyretin. It is approved for the treatment of Transthyretin Amyloid Cardiomyopathy.

Brand Name : Attruby

Molecule Type : Small molecule

Upfront Cash : Not Applicable

November 22, 2024

blank

Details:

Attruby (acoramidis) is a next-gen orally-administered, stabiliser of transthyretin (TTR). It is being indicated for the treatment of Transthyretin Amyloid Cardiomyopathy.


Lead Product(s): Acoramidis Hydrochloride

Therapeutic Area: Genetic Disease Brand Name: Attruby

Study Phase: ApprovedProduct Type: Small molecule

Sponsor: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable November 22, 2024

blank

02

Pharma, Lab & Chemical Expo
Not Confirmed
Pharma, Lab & Chemical Expo
Not Confirmed

Details : Attruby (acoramidis) is a next-gen orally-administered, stabiliser of transthyretin (TTR). It is being indicated for the treatment of Transthyretin Amyloid Cardiomyopathy.

Brand Name : Attruby

Molecule Type : Small molecule

Upfront Cash : Not Applicable

November 22, 2024

blank

Details:

The net proceeds will be used in the development of AG10 (acoramidis HCl). Which is being evaluated in the Phase III clinical trial studies for the treatment of Transthyretin Amyloid Cardiomyopathy.


Lead Product(s): Acoramidis Hydrochloride

Therapeutic Area: Genetic Disease Brand Name: AG10

Study Phase: Phase IIIProduct Type: Small molecule

Sponsor: J.P. Morgan

Deal Size: $250.0 million Upfront Cash: Undisclosed

Deal Type: Public Offering March 04, 2024

blank

03

Pharma, Lab & Chemical Expo
Not Confirmed
Pharma, Lab & Chemical Expo
Not Confirmed

Details : The net proceeds will be used in the development of AG10 (acoramidis HCl). Which is being evaluated in the Phase III clinical trial studies for the treatment of Transthyretin Amyloid Cardiomyopathy.

Brand Name : AG10

Molecule Type : Small molecule

Upfront Cash : Undisclosed

March 04, 2024

blank

Details:

BridgeBio grants Bayer an exclusive license to commercialize acoramidis, a small molecule stabilizer of TTR for ATTR-CM patients in Europe.


Lead Product(s): Acoramidis Hydrochloride

Therapeutic Area: Genetic Disease Brand Name: AG10

Study Phase: Phase IIIProduct Type: Small molecule

Sponsor: Bayer AG

Deal Size: Undisclosed Upfront Cash: $310.0 million

Deal Type: Licensing Agreement March 04, 2024

blank

04

Pharma, Lab & Chemical Expo
Not Confirmed
Pharma, Lab & Chemical Expo
Not Confirmed

Details : BridgeBio grants Bayer an exclusive license to commercialize acoramidis, a small molecule stabilizer of TTR for ATTR-CM patients in Europe.

Brand Name : AG10

Molecule Type : Small molecule

Upfront Cash : $310.0 million

March 04, 2024

blank

Details:

Bayer acquires commercialization rights for AG10 (acoramidis), an oral transthyretin stabilizer for ATTR CM in Europe.


Lead Product(s): Acoramidis Hydrochloride

Therapeutic Area: Genetic Disease Brand Name: AG10

Study Phase: Phase IIIProduct Type: Small molecule

Sponsor: Bayer AG

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Acquisition March 04, 2024

blank

05

Pharma, Lab & Chemical Expo
Not Confirmed
Pharma, Lab & Chemical Expo
Not Confirmed

Details : Bayer acquires commercialization rights for AG10 (acoramidis), an oral transthyretin stabilizer for ATTR CM in Europe.

Brand Name : AG10

Molecule Type : Small molecule

Upfront Cash : Undisclosed

March 04, 2024

blank

Details:

AG-10 (acoramidis) is an investigational, orally-administered small molecule stabilizer of transthyretin (TTR), evaluated in Phase 3 trials for Transthyretin Amyloid Cardiomyopathy treatment.


Lead Product(s): Acoramidis Hydrochloride

Therapeutic Area: Genetic Disease Brand Name: AG10

Study Phase: Phase IIIProduct Type: Small molecule

Sponsor: Alexion Pharmaceuticals

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable February 02, 2024

blank

06

Pharma, Lab & Chemical Expo
Not Confirmed
Pharma, Lab & Chemical Expo
Not Confirmed

Details : AG-10 (acoramidis) is an investigational, orally-administered small molecule stabilizer of transthyretin (TTR), evaluated in Phase 3 trials for Transthyretin Amyloid Cardiomyopathy treatment.

Brand Name : AG10

Molecule Type : Small molecule

Upfront Cash : Not Applicable

February 02, 2024

blank

Details:

The net proceeds will be used in the anticipated launch of AG10 (acoramidis HCl) as the potential backbone of therapy for transthyretin amyloid cardiomyopathy (ATTR-CM).


Lead Product(s): Acoramidis Hydrochloride

Therapeutic Area: Rare Diseases and Disorders Brand Name: AG10

Study Phase: Phase IIIProduct Type: Small molecule

Sponsor: Blue Owl Capital

Deal Size: $500.0 million Upfront Cash: $500.0 million

Deal Type: Financing January 18, 2024

blank

07

Pharma, Lab & Chemical Expo
Not Confirmed
Pharma, Lab & Chemical Expo
Not Confirmed

Details : The net proceeds will be used in the anticipated launch of AG10 (acoramidis HCl) as the potential backbone of therapy for transthyretin amyloid cardiomyopathy (ATTR-CM).

Brand Name : AG10

Molecule Type : Small molecule

Upfront Cash : $500.0 million

January 18, 2024

blank

Details:

AG10 (acoramidis) is an investigational, orally-administered small molecule designed to potently stabilize tetrameric transthyretin (TTR), being investigated for the treatment of transthyretin amyloid cardiomyopathy (ATTR-CM).


Lead Product(s): Acoramidis Hydrochloride

Therapeutic Area: Genetic Disease Brand Name: AG10

Study Phase: Phase IIIProduct Type: Small molecule

Sponsor: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable December 05, 2023

blank

08

Pharma, Lab & Chemical Expo
Not Confirmed
Pharma, Lab & Chemical Expo
Not Confirmed

Details : AG10 (acoramidis) is an investigational, orally-administered small molecule designed to potently stabilize tetrameric transthyretin (TTR), being investigated for the treatment of transthyretin amyloid cardiomyopathy (ATTR-CM).

Brand Name : AG10

Molecule Type : Small molecule

Upfront Cash : Not Applicable

December 05, 2023

blank

Details:

The net proceeds will fund the launch of AG10 (acoramidis), an investigational, orally-administered small molecule designed to potently stabilize tetrameric transthyretin (TTR), and company's upcoming Phase 3 readouts in achondroplasia, LGMD2I, and ADH1.


Lead Product(s): Acoramidis Hydrochloride

Therapeutic Area: Cardiology/Vascular Diseases Brand Name: AG10

Study Phase: Phase IIIProduct Type: Small molecule

Sponsor: Qatar Investment Authority

Deal Size: $250.0 million Upfront Cash: Undisclosed

Deal Type: Private Placement September 25, 2023

blank

09

Pharma, Lab & Chemical Expo
Not Confirmed
Pharma, Lab & Chemical Expo
Not Confirmed

Details : The net proceeds will fund the launch of AG10 (acoramidis), an investigational, orally-administered small molecule designed to potently stabilize tetrameric transthyretin (TTR), and company's upcoming Phase 3 readouts in achondroplasia, LGMD2I, and ADH1.

Brand Name : AG10

Molecule Type : Small molecule

Upfront Cash : Undisclosed

September 25, 2023

blank

Details:

AG10 (acoramidis) is an investigational, orally-administered small molecule designed to potently stabilize tetrameric transthyretin (TTR), being investigated for the treatment of transthyretin amyloid cardiomyopathy (ATTR-CM).


Lead Product(s): Acoramidis Hydrochloride

Therapeutic Area: Rare Diseases and Disorders Brand Name: AG10

Study Phase: Phase IIIProduct Type: Small molecule

Sponsor: Alexion Pharmaceuticals

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable July 17, 2023

blank

10

Pharma, Lab & Chemical Expo
Not Confirmed
Pharma, Lab & Chemical Expo
Not Confirmed

Details : AG10 (acoramidis) is an investigational, orally-administered small molecule designed to potently stabilize tetrameric transthyretin (TTR), being investigated for the treatment of transthyretin amyloid cardiomyopathy (ATTR-CM).

Brand Name : AG10

Molecule Type : Small molecule

Upfront Cash : Not Applicable

July 17, 2023

blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Digital Content read-more

Create Content with PharmaCompass, ask us

DATA COMPILATION #PharmaFlow

read-more
read-more

NEWS #PharmaBuzz

read-more
read-more

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty